This slide show reports on a pooled analysis that found up to a fivefold risk of second cancers among smokers, compared with cancer survivors who never smoked.
Surufatinib Combo Displays Promising Efficacy in Frontline ES-SCLC
All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.
Elevating Community Oncology Care: Insights From World GU 2025
A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.
Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population
Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.
Episode 13: Perspectives on Optimizing Community Care at World GU 2025
Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.
SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC
No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.
Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML
Ziftomenib yielded a median overall survival of 16.4 months in responders with NPM1-mutant AML who received ziftomenib in the phase 1b/2 KOMET-001 trial.